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Abstract: Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine 
therapy but retain canonical receptor signalling in the presence of selective ER antagonists. 
Numerous co-regulatory proteins, including enzymes that modulate the chromatin environment, 
control the transcriptional activity of the ER. Targeting ER co-regulators has therefore been 
proposed as a novel therapeutic approach. By assessing DNA-binding dynamics in ER-positive 
breast cancer cells, we have identified that the histone H3 lysine 9 demethylase enzymes, KDM3A 
and KDM4B, co-operate to regulate ER activity via an auto-regulatory loop that facilitates the 
recruitment of each co-activating enzyme to chromatin. We also provide evidence that suggests that 
KDM3A primes chromatin for deposition of the ER pioneer factor FOXA1 and recruitment of the 
ER-transcriptional complex, all prior to ER recruitment, therefore establishing an important 
mechanism of chromatin regulation involving histone demethylases and pioneer factors, which 
controls ER functionality. Importantly, we show via global gene-expression analysis that a 
KDM3A/KDM4B/FOXA1 co-regulated gene signature is enriched for pro-proliferative and ER-
target gene sets, suggesting that abrogation of this network could be an efficacious therapeutic 
strategy. Finally, we show that depletion of both KDM3A and KDM4B has a greater inhibitory effect 
on ER activity and cell growth than knockdown of each individual enzyme, suggesting that 
targeting both enzymes represents a potentially efficacious therapeutic option for ER-driven breast 
cancer.  
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1. Introduction 
Estrogen receptor (ER) signalling is important for breast cell homeostasis and transformation 
and remains the primary target for therapeutic intervention in breast cancer (BC). Typically, ER-
mediated transactivation is under tight control by a myriad of co-factors regulating the 
transcriptional competency of the receptor at numerous levels [1,2]. Several lines of evidence have 
indicated that chromatin deposition of pioneer factors FOXA1 and GATA3 at ER-target loci is critical 
for enabling appropriate DNA interactions of the receptor [3,4]. Subsequent recruitment of enzymes 
that modulate the chromatin environment, such as the histone acetyltransferase (HAT) p300, further 
stimulates ER signalling by enhancing recruitment of the RNA polymerase machinery [1,5]. 
Additional down-stream trans-acting factors, such as the bromodomain and extra-terminal (BET) 
protein BRD4, which promotes the elongation stage of mRNA synthesis, are also vital for ER-induced 
gene expression [6]. 
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Critically, aberrant activity of ER co-regulators drives the progression of BC [1,2,7–9]. In light of 
the fact that therapeutically targeting the ER directly in BC routinely fails, developing treatments that 
target critical ER co-regulators may provide an effective second-line treatment for endocrine therapy-
resistant disease. Understanding how these co-factors work and interact to regulate ER signalling is 
therefore crucial. 
Dynamic and selective methylation of lysines on histones H3 and H4 contributes a critical layer 
of epigenetic regulation to control gene transcription [10,11]. In contrast to lysine methylation of 
histone H3 lysine 4 (H3K4me) and 36 (H3K36me), which is principally associated with transcriptional 
activation, modification of histone H3 lysine 9 (H3K9me) and 27 (H3K27me) is enriched at 
transcriptionally inert regions of the genome. Additional complexity is provided by the existence of 
three isomeric states of methylation where target lysines can be either mono-, di-, or tri-methylated 
(me1, me2, me3). Histone methylation is catalysed by the Su(var)3-9, Enhancer-of-zeste, Trithorax 
(SET) domain family of histone lysine methyltransferases (KMTs) and is actively removed by histone 
lysine demethylase (KDM) enzymes, of which there are eight characterised families. All but one KDM 
family (KDM1) contain the catalytically active Jumanji-C (JmjC) demethylase domain [11–14]. 
Aberrant expression and activity of KMTs and KDMs and aberrant histone methylation patterns have 
been associated with cancer [15–18]. 
Two KDM enzymes, KDM3A and KDM4B, which remove transcriptionally repressive 
H3K9me1/me2 and H3K9me2/me3 marks, respectively, have both been associated with oncogenic 
roles in numerous cancer types, suggesting that perturbation of their activity may be efficacious as a 
therapeutic option [19–34]. Interestingly, KDM3A and KDM4B have both been identified as key 
regulators of a number of transcription factors, including androgen receptor (AR), p53, and HIF1α 
[22,30,32,35–39], and both play roles in embryonic stem cell development and metabolic homeostasis 
[40–46]. Furthermore, our previous findings have shown that both enzymes facilitate ER-mediated 
transcription by erasure of methylated H3K9 marks and promotion of ER chromatin binding at 
receptor target genes [20,47]. These observations suggest that KDM3A and KDM4B co-operate in 
their regulation of oncogenic signalling pathways. However, functional interplay between the two 
enzymes has not yet been investigated, particularly in the context of ER signalling. 
Here we show that KDM3A and KDM4B interact in BC cells and are involved in an auto-
regulatory loop whereby KDM4B regulates the expression of KDM3A, and KDM3A facilitates the 
recruitment of KDM4B to ER cis-regulatory elements. Subsequently, depletion of both KDM3A and 
KDM4B has a greater inhibitory effect on receptor activity than depletion of individual enzymes. We 
also provide evidence that KDM3A is required for chromatin occupancy of FOXA1, suggesting that 
the demethylase acts as a key regulator of pioneer factor-chromatin interactions and provides an 
appropriate environment for subsequent recruitment of trans-acting factors, such as BET proteins 
and p300. FOXA1 expression is also regulated by KDM4B, and we show that the transcriptomes of 
KDM3A, KDM4B, and FOXA1 overlap considerably. Gene set enrichment analysis indicates that co-
regulated genes are involved in ER signalling and cell cycle regulation, suggesting an important role 
for this regulatory network in driving ER-positive BC growth. In support of this, we demonstrate that 
depletion of KDM3A and KDM4B together has a greater inhibitory effect on cell proliferation than 
the depletion of each enzyme on its own. Together, our findings suggest a co-regulatory relationship 
between KDM3A and KDM4B on ER-signalling via FOXA1 regulation and deposition, and that 
targeting both KDM enzymes would be an efficacious therapeutic option for ER-positive and 
endocrine therapy-resistant disease. 
2. Results 
2.1. KDM3A Interacts with KDM4B and Regulates Chromatin Occupancy in ER-Positive Breast Cancer  
KDM3A and KDM4B both play roles in similar oncogenic signalling pathways [20,22,30,32,35–
39,47]. However, a co-operative role between the two enzymes has not been studied. We have 
previously shown that both KDM3A and KDM4B are required for ER recruitment to cis-regulatory 
elements of ER target genes [20,47]. The knockdown of KDM3A and KDM4B individually abrogated 
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the recruitment of the ER to oestrogen response elements (EREs) following oestrogen (E2) stimulation 
and abrogated the demethylation of target H3K9 methylation marks (KDM3A H3K9me1/2; KDM4B 
H3K9me3). We therefore investigated interactions between KDM3A and KDM4B in ER-positive BC. 
By probing endogenous KDM3A and KDM4B immunoprecipitates with reciprocal antibodies, 
we identified that KDM3A and KDM4B interact in MCF-7 (Figure 1A) and T47D (Supplementary 
Figure S1A) cells in both 10 nM E2-stimulated (+E2) and steroid-depleted (−E2) growth conditions. 
Given that our previous studies have shown that both KDM3A and KDM4B are enriched at cis-
regulatory elements of ER-target genes [20,47], we investigated whether the demethylases are co-
dependent upon each other for chromatin binding. Using chromatin immunoprecipitation (ChIP) in 
MCF-7 cells, we identified that KDM3A and KDM4B occupied cis-regulatory elements of pS2, GREB1, 
and CCND1 genes in the presence of E2 (Figure 1B,C). Importantly, chromatin binding of KDM3A 
was attenuated upon depletion of KDM4B and, reciprocally, KDM4B occupancy was diminished by 
the knockdown of KDM3A, suggesting that the demethylases work co-operatively to facilitate their 
chromatin association. Interestingly, through the course of these experiments, we observed that 
KDM4B depletion downregulated KDM3A mRNA and protein expression in MCF-7 cells, and 
KDM3A protein expression in T47D cells (Figure 1D; Supplementary Figure S1B). KDM4B depletion 
did not downregulate KDM3A mRNA expression, suggesting that the mechanisms of regulation, or 
temporal dynamics of this regulation, differs between the cell lines. The effect of KDM4B depletion 
on KDM3A expression likely explains reduced chromatin occupancy of KDM3A observed in our 
ChIP experiments. Critically, no effect on KDM4B protein expression was observed following 
KDM3A knockdown in either MCF-7 or T47D cells (Figure 1D), therefore suggesting that KDM3A 
specifically regulates the recruitment of KDM4B to ER target genes and that an auto-regulatory loop 
exists between the two enzymes. 
Considering the proposed co-operative role of KDM3A and KDM4B in ER-signalling, we next 
assessed the expression of the ER-target genes pS2 and CCND1 in dual KDM3A- and KDM4B-
depleted cells compared to the knockdown of individual enzymes. Consistent with our previous 
findings, depletion of both KDM3A and KDM4B down-regulated the expression of pS2 and CCND1 
(Supplementary Figure S2A,B). Importantly, expression of the ER-target genes in both MCF-7 and 
T47D cells was significantly lower in dual KDM3A- and KDM4B-depleted cells compared to the 
knockdown of individual enzymes (Figure 1E,F; Supplementary Figure S3), suggesting that interplay 
between KDM3A and KDM4B is required for ER-mediated transactivation. The effect of dual 
KDM3A- and KDM4B- depletion on respective KDM protein expression in MCF-7 and T47D cells can 
be seen in Supplementary Figure S3A. 
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Figure 1. KDM3A interacts with KDM4B and regulates chromatin occupancy. (A) MCF-7 cells grown 
in steroid-depleted (−E2) and 10 nM E2-supplemented (+E2) media were subject to 
immunoprecipitation (IP) using anti-KDM4B, anti-KDM3A, or isotype control (IgG) antibodies before 
western blot analysis (IB) using reciprocal antibodies. (B,C) MCF-7 cells were transiently transfected 
with either siSCR, siKDM3A#2, or siKDM4B#2 and grown in steroid-depleted conditions for 72 h 
prior to treatment with 10 nM E2 for 45 min followed by ChIP analysis using antibodies specific to 
KDM3A (B) or KDM4B (C) and isotype controls (IgG). ChIP using the isotype control antibody was 
performed on siSCR transfected cells in each experiment. Enrichment of KDM3A and KDM4B at pS2, 
GREB1, and CCND1 oestrogen response elements (EREs) was assessed by qPCR. Data are an average 
of 2 independent experiments ± SEM and are expressed relative to the level of enrichment measured 
in the siSCR transfected cells. P-values were determined by Dunnet’s multiple comparisons test (* 
denotes p < 0.05). (D) MCF-7 and T47D cells were transiently transfected with either siSCR, 
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siKDM3A#2, siKDM3A#3, or siKDM4B#2 and grown in steroid-depleted conditions for 72 h prior to 
treatment with 10 nM E2 for 4 h and then western blot analysis using antibodies specific to KDM4B, 
KDM3A, and α-tubulin. α-tubulin was used to compare protein loading between samples. (E,F) pS2 
and CCND1 gene expression in MCF-7 (E) or T47D (F) cells transfected with either an siRNA mixture 
of siSCR and siKDM3A#2 (red) or siSCR and siKDM4B#2 (blue) (single knockdowns) and compared 
with expression in cells transfected with an siRNA cocktail of siKDM3A#2 and siKDM4B#2 (red and 
blue) (dual knockdown). Cells were transfected and grown in steroid depleted media for 72 h prior 
to stimulation with E2 for 4 h and RNA extraction. qPCR data are an average of 3 repeats ± SEM and 
are expressed relative to gene expression in single gene knockdown cells. P values were determined 
by Students T test (* = p < 0.05). 
2.2. KDM3A Facilitates the Pioneering Role of FOXA1 in ER-Positive Breast Cancer 
Previous studies have demonstrated that chromatin association of KDM3A, but not KDM4B, 
precedes ER recruitment [20,47]. KDM3A was present at EREs in −E2 conditions, whereas KDM4B 
was actively recruited to EREs following E2 stimulation. Given that KDM3A chromatin occupancy is 
evident at quiescent ER-target genes, we speculated that KDM3A dependent recruitment of KDM4B 
may be due to chromatin regulation prior to ER activation. The pioneer factor FOXA1 plays a pivotal 
role in regulating chromatin occupancy and transcriptional competency of the ER in BC, with >50% 
of the ER cistrome overlapping with sites of FOXA1 deposition and approximately 95% of ER-target 
genes requiring FOXA1 for estrogenic activation, respectively [3]. What controls FOXA1 chromatin 
binding is still unclear, however evidence suggests that the presence of the transcriptionally 
permissive histone H3 lysine 4 methylation (H3K4me) mark and absence of transcriptionally 
repressive H3K9me marks are key determinants [48]. KDM3A knockdown was previously shown to 
increase H3K9 di-methylation at quiescent ER-target gene cis-regulatory sites [20]. We therefore 
speculated that KDM3A might be a regulator of FOXA1 DNA binding. To this end, BC cells depleted 
of KDM3A for 24 and 48 h were subject to chromatin extraction prior to western analysis using anti-
FOXA1 and anti-KDM3A antibodies. Knockdown of KDM3A reduced FOXA1 chromatin association 
in both MCF-7 and T47D cell lines (Figure 2A; Supplementary Figure S4A), which was not a 
consequence of reduced total FOXA1 protein or mRNA levels (Figure 2B; Supplementary Figure 
S4B,C). More specifically, KDM3A depletion reduced FOXA1 enrichment at promoter and enhancer 
elements of ER-target genes pS2 and GREB1 in MCF-7 cells by ChIP (Figure 2C; Supplementary 
Figure S4D). These results therefore suggest that KDM3A may act upstream of ER-recruitment in the 
ER signalling pathway and regulate FOXA1 deposition at these loci, therefore highlighting a potential 
mechanism of chromatin regulation prior to ER activation which in turn could regulate KDM4B 
recruitment to ER-target genes and the construction of the ER transcriptional complex. 
To further support this finding, we assessed if KDM3A controlled the chromatin association of 
other co-regulators associated with ER-mediated transactivation in BC cells. The binding of the acetyl 
transferase p300 and the bromodomain and extra-terminal (BET) protein BRD4 (both downstream 
co-regulators of ER signalling) was assessed by ChIP in MCF-7 cells depleted of KDM3A in the 
presence and absence of 10 nM E2. Consistent with activation of ER signalling, E2 treatment enhanced 
both p300 and BRD4 recruitment to regulatory elements of pS2 and GREB1 genes, but not a control 
region in the pS2 promoter, which does not bind ER (Supplementary Figure S5A). As expected, upon 
depletion of KDM3A, E2-stimulated recruitment of p300 and BRD4 at these loci was markedly 
reduced, which concurrently down-regulated the acetylation of histone H3 lysine 27 (H3K27ac) 
(Supplementary Figure S5A). Importantly, global p300 and BRD4 levels were not impacted by 
KDM3A knockdown (Supplementary Figure S5B), confirming the role of KDM3A in the construction 
of the ER transcriptional complex and demonstrating that KDM3A-driven H3K9me2 demethylation 
also induces histone acetylation. 
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Figure 2. KDM3A is required for FOXA1 recruitment to EREs. (A) MCF-7 cells were transiently 
transfected with either siSCR or siKDM3A#1. Cells were harvested after 24 and 48 h and cell 
fractionation performed prior to western blot analysis of proteins from the chromatin fraction using 
antibodies specific to KDM3A, FOXA1, and histone H3 as a loading control. (B) MCF-7 cells were 
transiently transfected with either siSCR or siKDM3A#1 and grown for 48 h prior to western blot 
analysis using antibodies specific to KDM3A, FOXA1, and α-tubulin. (C) MCF-7 cells were transiently 
transfected with either siSCR or siKDM3A#1 and grown in steroid-depleted conditions for 48 h prior 
to treatment with 10 nM E2 for 45 min followed by ChIP analysis using antibodies specific to FOXA1 
and isotype controls (IgG). ChIP using the isotype control antibody was performed on siSCR 
transfected cells in each experiment. Enrichment of FOXA1 at a pS2 proximal promoter ERE and 
GREB1 enhancer ERE was assessed by qPCR. Data are an average of 3 independent experiments ± 
SEM and are expressed relative to the level of enrichment measured in siSCR transfected cells. p-
values were determined by Student’s t-test (* denotes p < 0.05). 
2.3. KDM3A, KDM4B, and FOXA1 Have Overlapping Pro-Proliferative Gene Regulatory Profiles in ER 
Positive Breast Cancer 
KDM4B has previously been shown to regulate FOXA1 expression [47]. Coupled with the 
finding that KDM4B also regulates KDM3A expression and that KDM3A regulates both KDM4B and 
FOXA1 deposition at ER cis-regulatory sites, our data suggests a potential co-regulatory relationship 
between all three proteins to facilitate a cancer phenotype in ER-positive BC. To investigate this 
further, we examined the overlap between KDM3A-, KDM4B-, and FOXA1-regulated transcriptomes 
in MCF-7 cells by microarray analysis. Using a 1.5-fold cut-off for differentially-expressed genes 
between control and enzyme-depleted cells, we identified 229 genes that were co-regulated by all 
three enzymes, of which 213 (93%) were differentially expressed in the same direction (Figure 3A). 
Gene set enrichment analysis (GSEA) identified the enrichment of co-down-regulated genes in cell 
cycle processes, particularly genes that were involved in controlling the G2/M checkpoint, indicating 
a shared regulatory function in ER-positive BC growth (Figure 3B; Supplementary Table S1).  
Significant overlap was observed between KDM3A and FOXA1 gene regulatory profiles, with 
43% of KDM3A-regulated genes co-regulated by FOXA1 and 43% of FOXA1-regulated genes also 
regulated by KDM3A. Of 1075 KDM3A and FOXA1 co-regulated genes, 586 were down-regulated 
and 489 were up-regulated, with only 115 co-regulated genes regulated in opposing directions 
(Figure 3C), indicating shared transcriptomic profiles between KDM3A and FOXA1. Importantly, 
KDM3A knockdown had no impact on FOXA1 levels (Figure 2B) and, likewise, FOXA1 depletion by 
two independent siRNAs (siFOXA1#1 and siFOXA1#2) had no effect on KDM3A expression 
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(Supplementary Figures S4C and S6A), confirming that the effects of KDM3A and FOXA1 
knockdown is a consequence of altered transcriptional activity. As expected, GSEA of co-down-
regulated genes highlighted early and late estrogen-stimulated gene signatures, indicating a co-
regulatory role in ER-mediated gene transcription, but also identified other oncogenic signatures, 
including E2F and MYC (Figure 3D; Supplementary Table S2; Supplementary Figure S6B). GSEA also 
identified that a significant number of co-down-regulated genes are required for cell cycle processes 
(Figure 3D; Supplementary Table S2). Similarly, genes up-regulated in response to KDM3A and 
FOXA1 depletion were associated with growth inhibition and p53 pathway gene signatures 
(Supplementary Table S3; Supplementary Figure S6B). 
Interestingly, we identified that 53% and 48% of KDM4B-regulated genes were also regulated 
by KDM3A and FOXA1, respectively. Of 357 KDM4B and KDM3A co-regulated genes, 336 were 
differentially expressed in the same direction (168 down-regulated and 168 up-regulated), while out 
of 325 KDM4B and FOXA1 co-regulated genes, 282 were differentially expressed in the same 
direction (141 down-regulated and 141 up-regulated). Further, 63% of KDM4B and KDM3A co-
regulated genes were also regulated by FOXA1 and 75% of KDM4B and FOXA1 co-regulated genes 
were also regulated by KDM3A, showing the intrinsic link between KDM4B and KDM3A/FOXA1 
regulated gene signatures. As expected, KDM4B and FOXA1 co-down-regulated genes were 
associated with early estrogen response gene signatures and cell cycle processes (Supplementary 
Table S4). Consistent with our previous findings [20,47], genes down-regulated by depletion of both 
KDM3A and KDM4B were also associated with early and late estrogen response gene signatures 
(Figure 3E; Supplementary Table S5). KDM3A and KDM4B co-down-regulated genes were also 
involved in cell cycle regulation, suggesting that KDM3A and KDM4B co-operate in driving a pro-
proliferative phenotype (Figure 3E; Supplementary Table S5). 
Interestingly, the analysis of genes regulated independently by either KDM3A (n = 1190), 
KDM4B (n = 225), or FOXA1 (n = 1211) were not enriched for the cell cycle or cell proliferation 
processes. This suggests that the co-regulatory relationship between KDM3A/KDM4B/FOXA1 is key 
to ER-positive BC-growth and that abrogation of this regulatory axis could be a promising 
therapeutic approach. 
Cancers 2019, 11, 1122 8 of 19 
 
 
Figure 3. KDM3A, KDM4B, and FOXA1 have overlapping gene regulatory profiles. (A) MCF-7 cells 
were transiently transfected with either a non-silencing control siRNA (siSCR), siKDM3A#1, 
siKDM4B#1, or siFOXA1#1 and grown in steroid-depleted medium for 48 h prior to treatment with 
10 nM E2. RNA was extracted and samples hybridized to an Illumina HT12.2 Bead CHIP array. The 
number of KDM3A- (n = 2508), KDM4B- (n = 678), and FOXA1-regulated (n = 2497) genes (defined as 
genes significantly (p < 0.05) up or down regulated 1.5 fold upon knockdown compared to siSCR 
controls) was determined. Genes up- or down-regulated by more than one enzyme were classified as 
KDM3A/KDM4B/FOXA1 co-regulated genes (n = 1190 KDM3A/FOXA1 co-regulated genes; n = 357 
KDM3A/KDM4B co-regulated genes; 325 KDM4B/FOXA1 co-regulated genes; n = 229 
KDM3A/KDM4B/FOXA1 co-regulated genes). (B) GSEA of KDM3A/KDM4B/FOXA1 co-regulated 
genes demonstrates significant negative enrichment of genes associated with the 
HALLMARK_G2M_CHECKPOINT geneset and GO_MITOTIC_CELL_CYCLE geneset. NES = 
Nomalised Enrichment Score. p = nominal p-value. (C) Comparison between KDM3A- and FOXA1- 
up- and down-regulated genesets. (D) GSEA of KDM3A/FOXA1 co-regulated genes demonstrates 
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significant negative enrichment of genes associated with the 
HALLMARK_ESTROGEN_RESPONSE_LATE geneset and GO_CELL_CYCLE geneset. (E) GSEA of 
KDM3A/KDM4B co-regulated genes demonstrates significant negative enrichment of genes 
associated with the HALLMARK_ESTROGEN_RESPONSE_EARLY, 
HALLMARK_ESTROGEN_RESPONSE_LATE and HALLMARK_G2M_CHECKPOINT genesets 
and the GO_MITOTIC_CELL_CYCLE geneset. 
2.4. Dual Targetting of KDM3A and KDM4B is Potentially an Efficacious Therapeutic Strategy 
Considering that global transcriptomic analysis suggested that KDM3A and KDM4B co-operate 
to drive a pro-proliferative phenotype and that dual knockdown of each enzyme down-regulated 
ER-target genes more than individual KDM3A and KDM4B depletion, we next assessed the effect of 
dual-knockdown on BC cell growth. 
Previous work has shown that KDM4B is required for ER-positive BC growth both in vitro and 
in vivo, demonstrating its potential as a novel therapeutic target [28,29]. We have also previously 
shown that KDM3A depletion inhibits BC cell growth in vitro, demonstrating its therapeutic 
potential [20]. In a small mouse xenograft pilot study using a derivative MCF-7 cell line that stably 
expresses an inducible KDM3A-targeting shRNA under the control of doxycycline, we also provide 
proof-of-principle analysis that KDM3A depletion inhibits in vivo BC growth (Supplementary 
Figures S7 and S8). Although mouse numbers were small and therefore it is difficult to make 
conclusions from this analysis, data from this pilot study is consistent with our previous in vitro 
findings and suggests that KDM3A is a driver of BC cell proliferation. 
To test the effect of dual knockdown on cell growth, we compared the growth of both T47D and 
MCF-7 cells depleted of individual or both demethylases in E2-containing conditions after 96 h. In 
both cell lines, inhibition of cell growth was enhanced following dual knockdown compared to 
depletion of either enzyme on its own (Figure 4A,B (T47D); Supplementary Figure S9 (MCF-7)). 
Moreover, cell cycle analysis in T47D cells showed a decrease in cells in S-phase following dual-
knockdown, confirming enhanced inhibition of cell proliferation (Figure 4C). Considering the 
proposed co-regulatory relationship between KDM3A, KDM4B, and FOXA1, which facilitates a 
cancer phenotype in ER-positive BC, these data together suggest that targeting KDM3A and KDM4B 
simultaneously may be an efficacious therapeutic strategy. 
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Figure 4. Inhibition of cell growth is enhanced following dual knockdown of KDM3A and KDM4B. 
(A–C) T47D cells were grown in steroid-depleted conditions for 48 h and were then treated with 10 
nM E2 for 24 h before transfection with either siSCR or single and dual-knockdown siRNA mixtures 
(see materials and methods). Data labels indicate which KDM siRNAs were included in each siRNA 
mixture. (A) Cell confluence was measured every 6 h post-transfection by the Incucyte Zoom live cell 
imager. Data was normalised for each experimental arm to the cell confluence measured at 0 h. Data 
are the average of three independent experiments ± SEM. P-values were determined by Turkey’s 
multiple comparisons test (* denotes p < 0.05). (B) Cell counts were taken 96 h post transfection. Data 
are the average of three independent experiments ± SEM and are expressed relative to cell counts for 
siSCR transfected cells. P-values were determined by Turkey’s multiple comparisons test (* denotes 
p < 0.05). (C) Cells were harvested and stained with propidium iodide 96 h post transfection for flow 
cytometry analysis. Data shows the comparison of the percentage of cells in S-phase of the cell cycle 
between cells transfected with a single-knockdown siRNA mixture and a dual-knockdown siRNA 
mixture. Data labels indicate the siRNAs used in each mixture. Data are an average of 3 repeats ± SEM 
and are expressed relative to the percentage of S-phase cells in single gene knockdown cells. P values 
were determined by Students T test (* = p < 0.05). 
3. Discussion 
Estrogen receptor signalling involves a myriad of pioneer and co-regulatory proteins, 
demonstrating the complexity of transcriptional regulation of the receptor [1,2]. Approximately two 
thirds of BCs rely on ER-mediated transcriptional activation for growth. Endocrine therapy, which 
targets the interaction between the ER and estrogen, is currently the main therapeutic option. 
However, many women develop resistance to ER-targeting agents. The majority of resistant tumours 
maintain ER-signalling via numerous mechanisms including changes in activity of co-regulatory 
proteins and increased ER activation by kinase signalling pathways [49]. Targeting alternative 
proteins within the ER-signalling cascade is therefore emerging as a promising therapeutic option in 
both ER-positive and endocrine therapy-resistant disease. 
We have previously identified KDM3A and KDM4B as co-activators of ER-activity [20,47]. In 
this study, we identified that KDM3A and KDM4B interact in BC cells and are involved in an auto-
Cancers 2019, 11, 1122 11 of 19 
 
regulatory loop in which KDM4B regulates KDM3A expression and KDM3A facilitates the 
recruitment of KDM4B to EREs. KDM4B is also a regulator of expression of the ER pioneer protein 
FOXA1, and KDM3A appears to be required for the deposition of FOXA1 on chromatin and the 
subsequent recruitment of ER co-activator proteins and deposition of transcriptionally activating 
chromatin modifications, therefore highlighting a key co-regulatory role that these two KDM 
enzymes have on ER signalling (represented in Figure 5). Gene expression analysis following the 
knockdown of each of these proteins identified a KDM3A/KDM4B/FOXA1 co-regulatory 
transcriptomic profile enriched for genes involved in cell cycle regulation, suggesting that this is a 
key pro-proliferative regulatory network in ER-positive BC cells. Further global cistromic analysis of 
the effect of knockdown of KDM3A and KDM4B on the recruitment and deposition of each enzyme 
and of FOXA1 would further elucidate the interplay between these three proteins. 
 
Figure 5. Model of the KDM3A/KDM4B co-regulatory network. KDM4B is required for the expression 
of both KDM3A and FOXA1. KDM3A demethylates H3K9me1/me2 marks at EREs, which is required 
for the recruitment of both KDM4B and FOXA1, which in-turn is required for the recruitment of the 
ER-transcriptional complex, associated trans-activating chromatin modifications, and the expression 
of ER-target genes. 
FOXA1 is a key ER pioneer factor and is required for the transactivation of a large proportion of 
the canonical ER [3]. Considering the apparent co-regulatory role that KDM3A and KDM4B have on 
FOXA1 deposition, dual blockade of the enzymes may be an effective strategy to comprehensively 
abrogate the FOXA1/ER network. We identified that depletion of both KDM3A and KDM4B together 
has a greater inhibitory effect on both ER-target gene expression and BC cell growth than targeting 
either enzyme individually, suggesting that dual targeting of KDM3A and KDM4B may have 
significant clinical applications in ER-positive BC. The development of both pan-KDM and semi-
selective KDM family inhibitors have shown promise as anti-cancer therapeutic agents [50,51]. For 
example, semi-selective KDM4 inhibitors that abrogate KDM4B activity have been shown to be 
efficacious in inhibiting AR-signalling and growth in prostate cancer cells and to be effective in 
inhibiting the growth of MYC-driven neuroblastomas and breast cancer stem-like cells [52–55]. The 
conserved protein structure between JmjC-domain containing KDM families makes it challenging to 
develop potent single-enzyme selective inhibitors. However, the identification of a co-regulatory role 
between enzymes from different KDM families may suggest that a less selective approach could still 
be efficacious as a therapeutic strategy. 
Recent findings have suggested roles for both KDM3A and KDM4B in enhancing ER-signalling 
in endocrine-therapy resistant BC [56,57]. Considering the co-regulatory role of KDM3A and KDM4B 
in ER-signalling, dual targeting of these enzymes may provide new therapeutic strategies to address 
the unmet clinical need for treatments of this disease stage. In many endocrine therapy-resistant 
breast cancers, the antagonist-bound ER cistrome is distinct from that of the estrogen-activated ER, 
thereby creating an alternative ER-transcriptome that enables disease progression [58]. FOXA1 is 
overexpressed in endocrine therapy-resistant disease and mediates the alteration of ER-chromatin 
interactions [3,58,59]. Whether KDM3A plays a role in FOXA1 and ER deposition in endocrine 
therapy-resistant cells is currently unknown, although our previous data suggested that KDM3A 
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abrogates ER-signalling in a model of tamoxifen resistance [20]. Phosphorylation of KDM3A has also 
been shown to promote ER binding to the promoter of the oncogene HOXA1 in tamoxifen treated BC 
cells [57], suggesting that KDM3A plays a role in regulating ER recruitment in endocrine therapy-
resistant cells. Whether this effect is mediated by FOXA1 binding, however, is currently unknown.  
An alternative mechanism of endocrine-therapy resistance includes cross-talk between estrogen 
and hypoxia-mediated signalling pathways [60]. HIF-1α expression is associated with resistance to 
the ER antagonist tamoxifen and overactive HIF-1α is suggested to compensate for abrogated ER-
signalling in endocrine therapy-resistant disease [60,61]. The hypoxia inducible transcription factor, 
HIF-1α, is itself an ER-regulated gene and HIF-1α and ER have common gene targets [62]. KDM4B is 
a hypoxia- and estrogen-induced gene and has been proposed to be a key link between the two 
signalling pathways [63]. KDM3A is also regulated by HIF-1α and is a key modulator of HIF-1α 
signalling [37,38]. Considering the co-regulatory role between KDM3A and KDM4B in ER signalling, 
this suggests that both of these enzymes may be key modulators between the estrogen and hypoxia 
pathways. Inhibition of both enzymes may therefore be effective in treating hypoxia-induced 
endocrine therapy resistance. Hypoxia is also an independent oncogenic driver and both KDM3A 
and KDM4B are co-activators of HIF-1α signalling in multiple cancer types [33,37,38,64]. The study 
of a co-regulatory mechanism between KDM3A and KDM4B in hypoxic signalling may therefore also 
be beneficial for the development of novel therapeutic strategies to abrogate hypoxia driven tumours.  
As discussed, KDM3A and KDM4B have both been identified as key regulators of multiple 
transcription-factors [22,30,32,35–39]. To the best of our knowledge, this is the first study to 
demonstrate a direct co-regulatory link between KDM3A and KDM4B in a shared signalling 
pathway. It is possible that similar co-regulatory functions exist in other oncogenic signalling 
pathways. For example, both KDM3A and KDM4B have been shown to attenuate the expression of 
p53-regulated genes [35,36]. Methylation of K372 on p53 activates the recruitment of the transcription 
factor to target gene promoters. KDM3A demethylates K372 on p53 and therefore inhibits p53 
binding and transcriptional activity [35]. The depletion of KDM3A was shown to reactivate mutant 
p53 activity in breast cancer. The mechanism by which KDM4B attenuates p53-regulated gene 
activation has not been identified, however it was hypothesised that KDM4B upregulates a p53 
transcriptional repressor [36]. The findings of our study may therefore provide a mechanistic link 
between KDM4B and p53 attenuation via the upregulation of KDM3A, which warrants further 
investigation.  
Overall, the identification of a KDM3A/KDM4B co-regulatory axis that regulates FOXA1 and 
subsequent ER deposition on chromatin in breast cancer enhances the understanding of the 
mechanisms controlling ER-transcriptional activity. Crucially, the finding that dual KDM3A and 
KDM4B depletion has an additive anti-proliferative effect identifies a novel therapeutic approach for 
both ER-positive and endocrine therapy-resistant disease.  
4. Materials and Methods  
4.1. Cell Culture 
MCF-7, T47D, and HEK293T cells (ATCC) were maintained in RPMI-1640 media (Sigma, Saint 
Louis, MO, USA) containing 10% foetal-calf serum (FCS) (Gibco, Paisley, UK) and 1% 
penicillin/streptomycin (Sigma). For steroid-depletion experiments, cells were grown in phenol red-
free RPMI-1640 media (Gibco) supplemented with 10% serum stripped FCS (Hyclone, South Logan, 
UT, USA) and 1% penicillin/streptomycin. For estrogen stimulation experiments, 10 nM 17-β-
estradiol (E2) (Sigma) was added for the defined stimulation period. 
4.2. siRNA Transfection 
For knockdown experiments, three KDM3A-, two KDM4B-, two FOXA1-targeting, and control 
(siSCR) siRNAs were used (Sigma) (Supplementary Table S6). Cell lines were transfected using 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) with siRNA mixtures to a final 
concentration of 25 nM, as previously described [65]. For dual knockdown experiments, siRNA 
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mixtures of two individual siRNAs were made to a final concentration of 25 nM (12.5 nM per siRNA). 
To assess the expression of KDM3A, KDM4B, FOXA1, p300, BRD4, and α-tubulin, transfected cells 
were harvested in SDS-sample buffer (10% β-mercaptoethanol, 125 mM Tris-HCl (pH 6.8), 2% SDS, 
10% glycerol, and 0.005% bromophenol blue) and were subject to polyacrylamide gel electrophoresis 
prior to immunoblotting with specific antibodies as described in [66] (Supplementary Table S7). For 
the chromatin extraction experiments, transfected cells underwent cell fractionation using the NE-
PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific, Waltham, MA, USA). Cell fractions 
were harvested in SDS-sample buffer and probed for KDM3A, FOXA1, and histone H3 by western 
blot. For gene expression analysis, RNA was extracted from transfected cells using TRIzol (Ambion, 
Austin, TX, USA) and cDNA generated for analysis by quantitative PCR (qPCR) [65] (see 
Supplementary Table S8 for primer sequences). 
4.3. Microarray and Gene Set Enrichment Analysis 
MCF-7 cells were transfected with either siSCR or siKDM4B#1, as described above, and grown 
for 48 h in steroid-depleted conditions prior to 4 h E2 stimulation and RNA extraction. Gene 
expression data was obtained by hybridising duplicate samples to Illumina HT-12 version 4 
BeadChips. Raw microarray data was analysed using GenomeStudio Gene Expression Module 
(Illumina, San Diego, CA, USA). Differential gene expression analysis was performed using quantile-
normalised data incorporating multiple sample testing correction using Benjamini and Hochberg 
false discovery rate (p < 0.05). Gene expression data from the siSCR transfected samples was used as 
the reference gene expression dataset. Genes up- or down-regulated 1.5 fold in KDM4B-depleted 
versus siSCR transfected cells were identified by dividing siKDM4B#1 transfected cell gene signal 
intensities by siSCR transfected cell gene signal intensities. Only genes with a differential p-value < 
0.05 (as determined by the GenomeStudio Illumina Custom differential expression algorithm) were 
used in subsequent analyses. Genes were further filtered to exclude genes with an insignificant 
detection p-value (p > 0.05) and to exclude genes without a gene symbol/ID and those with only locus 
specific entries. 
For KDM3A and FOXA1 regulated gene signatures, MCF-7 cells were transfected with siSCR, 
siKDM3A#1, or siFOXA1#1, as described above, and grown for 48 h in steroid-depleted conditions 
prior to 6 h E2 stimulation and RNA extraction. Gene expression data was obtained by hybridising 
triplicate samples to Illumina HT-12 version 4 BeadChips. Data was analysed as described above. 
siKDM3A and siFOXA1 regulated genes were identified as genes up- or down- regulated 1.5 fold in 
siSKDM3A#1/siKDM4B#1 transfected cells compared to E2 treated siSCR transfected cells. All 
microarray data discussed in this publication have been deposited in NCBI’s Gene Expression 
Omnibus (GEO-https://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series 
accession numbers GSE135427 and GSE124270. 
Genes that were KDM3A/KDM4B/FOXA1 co-regulated were analysed using the Gene Set 
Enrichment Analysis (GSEA) software (Broad Institute, Cambridge, MA, USA; [67,68]). Identified co-
regulated genes were ranked for analysis based on the mean differentiation score calculated by the 
GenomeStudio software. Ranked lists were compared against the hallmark gene set and GO gene 
sets from the Molecular Signatures Database v6.2 (MSigDB, Broad Institute). Enriched gene sets with 
a nominal p-value < 0.05 were included in subsequent analyses. 
4.4. Co-Immunoprecipitation 
MCF-7 and T47D cells were grown for 72 h in steroid-depleted or E2-stimulated growth 
conditions in 90 mm dishes. Following incubation, cells were lysed in 1 mL of lysis buffer (50 mM 
Tris, 150 mM NaCl, 1 mM DTT, 1 mM PMSF, 1% NP40, 1× Protease Inhibitor Cocktail (Roche, Basel, 
Switzerland)) and subject to immunoprecipitation using 2 µg of KDM3A, KDM4B, or isotype control 
antibodies (Supplementary Table S7) and Protein G Sepharose beads (GE Healthcare, Chicago, IL, 
USA). Resultant immunoprecipitates were boiled in SDS sample buffer and subject to western 
analysis using antibodies specific for KDM3A and KDM4B. 
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4.5. Chromatin Immunoprecipitation (ChIP) 
Cells were grown in steroid-depleted medium for 48 h (FOXA1, p300, BRD4, H3K27ac ChIPs) or 
72 h (KDM3A and KDM4B ChIPs) and were then treated with vehicle or E2 for 45 min. Cells were 
harvested and subject to ChIP, as previously described [47], using 2 µg of indicated antibodies 
(Supplementary Table S7). Following ChIP, eluted DNA and input samples underwent cross-link 
reversal and qPCR analysis using primers specific to estrogen response elements in either the pS2 
promoter, GREB1, CCND1 enhancers, or a pS2 control region which does not bind ER (Supplementary 
Table S8 for primer sequences). Data was calculated as % input as previously described [47] and 
presented as the average fold difference of % input between different experimental arms of at least 
two independent experiments (detailed in figure legends).  
4.6. Cell Growth and Cell Cycle Analysis 
MCF-7 and T47D cells were grown in steroid-depleted conditions for 48 h and were then treated 
with E2 for 24 h before transfection with dual knockdown siRNA mixtures. Briefly, cells were 
transfected with either 25 nM siSCR, 25 nM siRNA mixtures of siSCR with either siKDM3A#2, 
siKDM3A#3, or siKDM4B#2 (single gene knockdowns—siSCR/si3A#2, siSCR/si3A#3, siSCR/si4B#2), 
or 25 nM siRNA mixtures of siKDM3A#2 and siKDM4B#2 or siKDM3A#3 and siKDM4B#2 (dual gene 
knockdowns—si3A#2/si4B#2, si3A#3/si4B#2). Cells were grown for 96 h and either monitored for cell 
growth by cell counts, by Incucyte Zoom live cell imaging (Essen Bioscience, Ann Arbor, MI, USA), 
or cell cycle analysis by propidium iodide flow cytometry as previously described [20]. The Incucyte 
Zoom live cell imager was used to assess relative cell confluence every 6 h between transfected cells, 
as described in [20]. Cell confluence for each experimental arm was normalised to the 0 h time point 
(point of transfection) and the relative change in cell confluence calculated for each time point 
thereafter. Data are presented as the mean relative cell confluence at each time point. Cells counts 
were performed using a haemocytometer at the end of the experiment. Data were represented as the 
average fold difference in cell number relative to siSCR transfected cells.  
4.7. Development of MCF-7-shRNA Cells 
A pTRIPZ-inducible lentiviral KDM3A targeting shRNA vector (Thermo Scientific) was 
packaged into a virus in HEK293T cells using pMD2.G and pPAX2 packaging vectors. Briefly, 80% 
confluent cells growing in 150 mm tissue culture dishes were transfected using TransIT-LT1 
Transfection Reagent (Geneflow, Lichfield, UK) with 2.25 µg pMD2.G, 6.75 µg pPAX2, and 9 µg 
pTRIPZ following the manufacturer’s instructions. Twenty-four hours post transfection, tissue 
culture media was replaced. Over the following 48 h, virus containing media was harvested and viral 
particles isolated by ultracentrifugation. The virus was re-suspended in 1 mL of RPMI-1640 
containing 1 µg/mL puromycin. 
MCF-7 cells growing in 30 mm culture dishes were transduced with 100 µL of re-suspended 
virus and treated with 5 µg/mL of polybrene and 1 µg/mL puromycin. A clonal population of MCF-
7-shRNA cells were produced. shRNA expression and KDM3A depletion was confirmed by treating 
cells for 96 h with vehicle or 1 µg/mL doxycycline and assessing RFP expression by fluorescent 
microscopy, KDM3A protein levels by western blot, and KDM3A, pS2, and GREB1 expression by 
qPCR. To assess the phenotypic effects of shRNA-induced KDM3A depletion, cells were plated in 1 
µg/mL doxycycline-containing media and cell growth analysed by the Incucyte Zoom live cell 
imager. Cells were also subject to cell counts and propidium iodide cell cycle analysis 96 h post 
plating. 
4.8. In Vivo Mouse Study and Immunohistochemistry 
All of the in vivo experiments were reviewed and approved by the relevant institutional animal 
welfare committees (Project License—PPL 60/4222) and performed according to the Guidelines for 
the Welfare set out by an ad hoc committee of the National Cancer Research Institute [69] and national 
law. Female athymic CD1 nude mice (Charles Rivers, Ramsgate, Kent, UK) were maintained 
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individually in ventilated cages and handled in lamina flow hoods under specific pathogen free 
conditions. 
Ten CD1 nude mice implanted with 60 day slow release 17β-estradiol (0.18 mg/pellet) pellets 
(Innovative Research of America) were subcutaneously injected with MCF-7-shRNA cells, 1 × 107 cells 
in 50 µL per animal, and were suspended in a mixture of matrigel (BD biosciences, San Jose, CA, 
USA) and RPMI growth media (1:1 v:v). Engraftments of MCF-7-shRNA cells were successful in six 
mice and xenografts used in subsequent analyses. Five days following implantation, half the mice 
were given continuous access to doxycycline supplemented feed (625 ppm doxycycline per 1 kg Diet, 
Special Diets Services) while the control group were provided non-supplemented feed. Tumours 
were measured using callipers at least every 4 days and all xenografts were excised 51 days after 
implantation, or if they had reached a diameter of 1 cm in any direction before that point. 
Resultant xenografts were stored in formalin and were paraffin embedded before sectioning. 
Antigen retrieval was performed by pressure cooking sectioned slides in 10 mM citrate pH 6.0 before 
immunohistochemistry using anti-KDM3A, -H3K9me2, and -H3K27ac antibodies (Supplementary 
Table S7) as described [70]. Stained slides were scanned using an Aperio CS2 (Leica Biosystems, 
Wetzlar, Germany) and analysed using Spectrum TM software (Aperio) to generate Histoscores for 
each sample. Briefly, stained nuclei were given a score of 0, 1, 2, or 3 based on staining intensity. An 
overall histoscore was calculated using the equation: (% of nuclei with a score of 1) + 2 × (% of nuclei 
with score of 2) + 3 × (% of nuclei with score of 3). 
5. Conclusions 
The present study provides evidence of a co-operative role between the histone demethylase 
enzymes KDM3A and KDM4B in regulating ER-signalling in models of breast cancer. This is the first 
study to demonstrate a co-operative role between these two enzymes, with data suggesting that the 
KDM3A/KDM4B co-regulatory axis regulates FOXA1 and subsequent ER deposition on chromatin. 
Importantly, the finding that dual depletion of KDM3A and KDM4B has a greater anti-proliferative 
effect than depletion of either enzyme on its own, suggests that dual targeting of these enzymes may 
be a novel therapeutic approach for both ER-positive and endocrine therapy-resistant disease. 
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key regulator of p300 and BRD4 chromatin function, Figure S6: GSEA of genes down-regulated upon FOXA1 
knockdown, Figure S7: Effect of doxycycline induced KDM3A knockdown in MCF-7-shKDM3A cells, Figure S8: 
In vivo effect of doxycycline induced KDM3A knockdown in MCF-7-shKDM3A mouse xenografts, Figure S9: 
Inhibition of cell growth is enhanced following KDM3A- and KDM4B-dual knockdown compared to the 
depletion of either enzyme on its own in MCF-7 cells. Table S1: Gene Set Enrichment analysis of 
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